Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04775550
What this trial is testing

DARA RVD For High Risk SMM

Who this might be right for
High-risk Smoldering Multiple MyelomaMultiple Myeloma
Omar Nadeem, MD 61
Testing effectiveness (Phase 2)Ended earlyNCT00240162
What this trial is testing

PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Washington University School of Medicine 21
Large-scale testing (Phase 3)UnknownNCT00002989
What this trial is testing

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
European Organisation for Research and Treatment of Cancer - EORTC 207
Testing effectiveness (Phase 2)Study completedNCT02034110
What this trial is testing

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Who this might be right for
Cancer
Novartis Pharmaceuticals 206
Testing effectiveness (Phase 2)UnknownNCT00311337
What this trial is testing

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Who this might be right for
Multiple Myeloma
University of Wuerzburg 61
Testing effectiveness (Phase 2)Study completedNCT02416206
What this trial is testing

High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Northside Hospital, Inc. 65
Testing effectiveness (Phase 2)Study completedNCT00258206
What this trial is testing

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 21
Large-scale testing (Phase 3)Study completedNCT00551928
What this trial is testing

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaNewly Diagnosed Patients
Fondazione EMN Italy Onlus 402
Not applicableStudy completedNCT05150353
What this trial is testing

Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)

Who this might be right for
AmyloidSystemic Amyloidosis
GCS Ramsay Santé pour l'Enseignement et la Recherche 128
Testing effectiveness (Phase 2)Study completedNCT00833560
What this trial is testing

Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Who this might be right for
Multiple Myeloma
Janssen-Cilag G.m.b.H 401
Testing effectiveness (Phase 2)Study completedNCT00006219
What this trial is testing

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic
Large-scale testing (Phase 3)Study completedNCT03651128
What this trial is testing

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 386
Testing effectiveness (Phase 2)Study completedNCT00781170
What this trial is testing

Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma

Who this might be right for
Multiple MyelomaStem Cell Transplantation
Universitätsklinikum Hamburg-Eppendorf 20
Testing effectiveness (Phase 2)WithdrawnNCT02114502
What this trial is testing

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT04813653
What this trial is testing

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Tel-Aviv Sourasky Medical Center 3
Testing effectiveness (Phase 2)WithdrawnNCT00004039
What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Looking for participantsNCT04558931
What this trial is testing

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karolinska Institutet 62
Large-scale testing (Phase 3)UnknownNCT02270307
What this trial is testing

MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis

Who this might be right for
LeukemiaMultiple Myeloma
National Research Center for Hematology, Russia 40
Large-scale testing (Phase 3)Study completedNCT02252172
What this trial is testing

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 737
Testing effectiveness (Phase 2)Ended earlyNCT02906332
What this trial is testing

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 12
Next Page